Targeting cell changes in pancreatic cancer to improve treatment outcomes
Optimal control models of epithelial-mesenchymal transition for the design of pancreas cancer combination therapy
This study is looking at how pancreatic cancer cells adapt to treatments and become tougher to kill, and it's trying to find the best combinations of drugs to help make those treatments work better for patients like you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10670987 on NIH RePORTER |
What this research studies
This research investigates how pancreatic cancer cells change in response to treatment, making them more resistant to therapies. By focusing on the process known as epithelial-mesenchymal transition (EMT), the study aims to identify specific drug combinations and schedules that can effectively counteract these changes. The approach involves using advanced systems biology techniques to analyze cell signaling pathways and develop a strategy for combination therapies that enhance treatment effectiveness while reducing side effects. Patients may benefit from more effective treatment options tailored to their specific cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that significantly enhance survival rates for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promise in targeting EMT in other cancers, suggesting that this approach may also be effective in pancreatic cancer.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Lazzara, Matthew J — University of Virginia
- Study coordinator: Lazzara, Matthew J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.